Since upregulated SMYD3 shapes the immunosuppressive microenvironment in ccRCC through the SREBP1‐CD47 axis, pharmacological inhibition of SMYD3 may have a synergistic effect with PD‐1 inhibitors to achieve increased tumor therapeutic efficacy. The gene discussed is SMYD3; the disease is nonpapillary renal cell carcinoma.